Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2009

View Archived Issues

Boehringer Ingelheim claims new oncolytic PI3K inhibitors in recent patent

New PAI-1 inhibitors claimed by Kowa for treating thrombotic disorders

Novel cannabinoid CB1 receptor antagonists discovered at Schering-Plough

Novo Nordisk reviews Q4 progress

iTherX to initiate proof-of-concept study for ITX-5061 in hepatitis C

Prasugrel receives approval recommendation from FDA Advisory Committee

Pfizer's Sutent is recommended as first-line treatment for kidney cancer

Allos reports results from pivotal pralatrexate trial in peripheral T-cell lymphoma

GSK and Theravance announce positive results from three fluticasone furoate trials

OncoGenex provides 2-year survival data from ongoing OGX-011 trial

Abraxis BioScience launches Abraxane in Germany

JMR-132, AN-162 demonstrate ovarian tumor growth inhibition in xenograft models

Alseres completes enrollment in Altropane POET-2 phase III program

Medivir selects MIV-710 as a candidate drug for osteoporosis and osteoarthritis

Novel T-type calcium channel inhibitors discovered by Merck & Co. researchers

Novel TNF-alpha production inhibitors reported by Daiichi Sankyo for treatment of sepsis

CyDex successfully completes phase II clinical trial of Captisol-Enabled nasal spray in SAR

Isoform-selective phospholipase D inhibitors developed at Vanderbilt University

Waiting period expires for MAP and AstraZeneca's agreement for budesonide

Warner Chilcott acquires NexMed's alprostadil for erectile dysfunction

Human ProIslet Peptide stimulates islet neogenesis

FDA approves Galderma's Vectical for mild to moderate plaque psoriasis

Peregrine announces results from phase II clinical trial of bavituximab in NSCLC

European Commission clears acquisition of Zentiva by sanofi-aventis

FDA Advisory Committee favors approval of DX-88 for hereditary angioedema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...